Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
J Recept Signal Transduct Res ; 37(2): 149-166, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27400858

RESUMEN

Estrothiazine (ESTZ) is a weak estrogen sharing structural similarities with coumestrol. ESTZ failed to compete with [3H]17ß-estradiol ([3H]17ß-E2) for binding to the estrogen receptor α (ERα), questioning its ability to interact with the receptor. However, detection by atomic force spectroscopy (AFS) of an ESTZ-induced ERα dimerization has eliminated any remaining doubts. The effect of the compound on the proliferation of ERα-positive and negative breast cancer cells confirmed the requirement of the receptor. The efficiency of ESTZ in MCF-7 cells was weak without any potency to modify the proliferation profile of estradiol and coumestrol. Growth enhancement was associated with a proteasomal degradation of ERα without substantial recruitment of LxxLL coactivators. This may be related to an unusual delay between the acquisition by the receptor of an ERE-binding capacity and the subsequent estrogen-dependent transcription. A complementary ability to enhance TPA-induced AP-1 transcription was observed, even at concentrations insufficient to activate the ERα, suggesting a partly independent mechanism. ESTZ also rapidly and transiently activated ERK1/2 likely through membrane estrogenic pathways provoking a reorganization of the actin network. Finally, the systematic absence of biological responses with an ESTZ derivative unable to induce ERα dimerization stresses the importance of this step in the action of the compound, as reported for conventional estrogens. In view of the existence of many other ERα modulators (endocrine disruptors such as, for example, pesticides, environmental contaminants or phytoestrogens) with extremely weak or similar apparent lack of binding ability, our work may appear as pilot investigation for assessing their mechanism of action.


Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Receptor alfa de Estrógeno/metabolismo , Tiazinas/administración & dosificación , Transcripción Genética , Sitios de Unión , Neoplasias de la Mama/genética , Dimerización , Estradiol/metabolismo , Receptor alfa de Estrógeno/genética , Femenino , Humanos , Células MCF-7 , Fitoestrógenos , Unión Proteica/genética , Espectrofotometría Atómica , Tiazinas/química , Factor de Transcripción AP-1/genética , Factor de Transcripción AP-1/metabolismo
2.
Appl Microbiol Biotechnol ; 101(1): 139-145, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27488682

RESUMEN

Polyphosphate kinases (PPK) from different bacteria, including that of Streptomyces lividans, were shown to contain the typical HKD motif present in phospholipase D (PLD) and showed structural similarities to the latter. This observation prompted us to investigate the PLD activity of PPK of S. lividans, in vitro. The ability of PPK to catalyze the hydrolysis of phosphatidylcholine (PC), the PLD substrate, was assessed by the quantification of [3H]phosphatidic acid (PA) released from [3H]PC-labeled ELT3 cell membranes. Basal cell membrane PLD activity as well as GTPγS-activated PLD activity was higher in the presence than in absence of PPK. After abolition of the basal PLD activity of the membranes by heat or tryptic treatment, the addition of PPK to cell membranes was still accompanied by an increased production of PA demonstrating that PPK also bears a PLD activity. PLD activity of PPK was also assessed by the production of choline from hydrolysis of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) in the presence of the Amplex Red reagent and compared to two commercial PLD enzymes. These data demonstrated that PPK is endowed with a weak but clearly detectable PLD activity. The question of the biological signification, if any, of this enzymatic promiscuity is discussed.


Asunto(s)
Fosfolipasa D/metabolismo , Fosfotransferasas (Aceptor del Grupo Fosfato)/metabolismo , Streptomyces lividans/enzimología , Secuencias de Aminoácidos , Membrana Celular/enzimología , Colina/metabolismo , Hidrólisis , Ácidos Fosfatidicos/metabolismo , Fosfatidilcolinas/metabolismo , Fosfolipasa D/química , Fosfolipasa D/genética , Fosfotransferasas (Aceptor del Grupo Fosfato)/química , Fosfotransferasas (Aceptor del Grupo Fosfato)/genética , Conformación Proteica , Streptomyces lividans/genética
3.
Biochem J ; 472(1): 97-109, 2015 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-26371374

RESUMEN

The ERα (oestrogen receptor α)-derived peptide ERα17p activates rapid signalling events in breast carcinoma cells under steroid-deprived conditions. In the present study, we investigated its effects in ELT3 leiomyoma cells under similar conditions. We show that it activates ERK1/2 (extracellular-signal-regulated kinase 1/2), the Gαi protein, the trans-activation of EGFR (epidermal growth factor receptor) and, finally, cell proliferation. It is partially internalized in cells and induces membrane translocation of ß-arrestins. The activation of ERK1/2 is abolished by the GPR30 (G-protein-coupled receptor 30) antagonist G15 and GPR30 siRNA. When ERα is down-regulated by prolonged treatment with E2 (oestradiol) or specific ERα siRNA, the peptide response is blunted. Thus the simultaneous presence of GPR30 and ERα is required for the action of ERα17p. In addition, its PLM sequence, which interferes with the formation of the ERα-calmodulin complex, appears to be requisite for the phosphorylation of ERK1/2 and cell proliferation. Hence ERα17p is, to our knowledge, the first known peptide targeting ERα-GPR30 membrane cross-talk and the subsequent receptor-mediated biological effects.


Asunto(s)
Receptor alfa de Estrógeno/metabolismo , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Oligopéptidos/farmacología , Receptores Acoplados a Proteínas G/metabolismo , Secuencia de Aminoácidos , Animales , Arrestinas/metabolismo , Western Blotting , Calmodulina/metabolismo , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Activación Enzimática/efectos de los fármacos , Receptores ErbB/metabolismo , Estradiol/farmacología , Receptor alfa de Estrógeno/química , Receptor alfa de Estrógeno/genética , Datos de Secuencia Molecular , Oligopéptidos/química , Oligopéptidos/farmacocinética , Fosforilación/efectos de los fármacos , Unión Proteica/efectos de los fármacos , Transporte de Proteínas/efectos de los fármacos , Interferencia de ARN , Ratas , Receptor Cross-Talk/efectos de los fármacos , Receptores Acoplados a Proteínas G/genética , beta-Arrestinas
4.
Endocrinology ; 149(9): 4669-79, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18723875

RESUMEN

We investigated the regulation of the sphingosine kinase (SphK)/sphingosine-1-phosphate (S1P) axis and its role during pregnancy in the rat myometrium. SphK1 and SphK2 were coexpressed in myometrium during gestation. The levels and activity of SphK1/2 were modest at midgestation (d 12), increased at d 19 and progressively declined to low at postpartum. Similar patterns were observed for the phosphorylation of ERK and protein kinase C (PKC). Inhibition of PKC and ERK reduced SphK1/2 activity. In late pregnancy, levels of cyclooxygenase 2 (COX2) increased in parallel to SphK levels. Using a pharmacological approach, we demonstrated that in primary cultures of myometrial cells from d-19 pregnant rats, induction of COX2 was mediated by 4beta-phorbol 12,13-dibutyrate and IL-1beta through sequential activation of PKC, ERK1/2, and SphK1. S1P produced by SphK1 was released in the medium. Addition of S1P, IL-1beta or 4beta-phorbol 12,13-dibutyrate enhanced COX2 levels via Gi protein. Interestingly, S1P was also released by myometrial tissues at late gestation. This event was dependent on PKC/ERK/SphK1. By contrast, in d-12 myometrial tissues, the release of S1P was markedly reduced in association with low levels of SphK1 and COX2. However, prolonged incubation of myometrium from midgestation led to the induction of COX2. This effect was blocked by SphK inhibitors, providing evidence of the close relationship between SphK activity and COX2 induction in rat myometrium. Overall, our findings provided insight into the physiological relevance of the SphK activation and S1P release in uterine smooth muscle during gestation.


Asunto(s)
Ciclooxigenasa 2/fisiología , Lisofosfolípidos/metabolismo , Miometrio/metabolismo , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Esfingosina/análogos & derivados , Animales , Células Cultivadas , Ciclooxigenasa 2/metabolismo , Activación Enzimática/fisiología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Femenino , Edad Gestacional , Modelos Biológicos , Miometrio/enzimología , Periodo Posparto/metabolismo , Embarazo , Proteína Quinasa C/metabolismo , Ratas , Ratas Wistar , Transducción de Señal/fisiología , Esfingosina/metabolismo
5.
Antioxid Redox Signal ; 26(1): 15-27, 2017 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-27392575

RESUMEN

AIMS: Circulating microparticles (MPs) from metabolic syndrome patients and those generated from apoptotic T cells induce endothelial dysfunction; however, the molecular and cellular mechanism(s) underlying in the effects of MPs remain to be elucidated. RESULTS: Here, we show that both types of MPs increased expression of endoplasmic reticulum (ER) stress markers, X-box binding protein 1, p-eukaryotic translation initiation factor 2 α, and CHOP, and nuclear translocation of activating transcription factor 6 on human aortic endothelial cells (HAoECs). MPs decreased in vitro nitric oxide release by HAoECs, whereas in vivo MP injection into mice impaired the endothelium-dependent relaxation induced by acetylcholine. These effects were prevented when ER stress was inhibited, suggesting that ER stress is implicated in the endothelial effects induced by MPs. MPs affected mitochondrial function and evoked sequential increase of cytosolic and mitochondrial reactive oxygen species (ROS). Pharmacological inhibition of ER stress and silencing of neutral sphingomyelinase (SMase) with siRNA abrogated all MP-mediated effects. Neutralization of Fas ligand carried by MPs abolished effects induced by both MP types, whereas neutralization of low-density lipoprotein receptor on endothelial cells prevented T-lymphocyte MP-mediated effects. Innovation and Conclusion: Collectively, endothelial dysfunction triggered by MPs involves temporal cross talk between ER and mitochondria with respect to spatial regulation of ROS via the neutral SMase and interaction of MPs with Fas and/or low-density lipoprotein receptor. These results provide a novel molecular insight into the manner MPs mediate vascular dysfunction and allow identification of potential therapeutic targets to treat vascular complications associated with metabolic syndrome. Antioxid. Redox Signal. 26, 15-27.


Asunto(s)
Micropartículas Derivadas de Células/metabolismo , Retículo Endoplásmico/metabolismo , Células Endoteliales/metabolismo , Mitocondrias/metabolismo , Estrés Oxidativo , Transducción de Señal , Citosol/metabolismo , Estrés del Retículo Endoplásmico , Activación Enzimática , Proteína Ligando Fas/metabolismo , Humanos , Activación de Linfocitos , Síndrome Metabólico/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Receptores de Superficie Celular/metabolismo , Esfingomielina Fosfodiesterasa/metabolismo , Linfocitos T/inmunología , Linfocitos T/metabolismo , Receptor fas/metabolismo
6.
MAbs ; 8(7): 1371-1385, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27390909

RESUMEN

Metastatic melanoma is an aggressive cancer with a poor prognostic, and the design of new targeted drugs to treat melanoma is a therapeutic challenge. A promising approach is to produce monoclonal antibodies (mAbs) against the endothelin B receptor (ETB), which is known to be overexpressed in melanoma and to contribute to proliferation, migration and vasculogenic mimicry associated with invasiveness of this cancer. We previously described rendomab-B1, a mAb produced by DNA immunization. It is endowed with remarkable characteristics in term of affinity, specificity and antagonist properties against human ETB expressed by the endothelial cells, but, surprisingly, had poor affinity for ETB expressed by melanoma cells. This characteristic strongly suggested the existence of a tumor-specific ETB form. In the study reported here, we identified a new mAb, rendomab-B4, which, in contrast to rendomab-B1, binds ETB expressed on UACC-257, WM-266-4 and SLM8 melanoma cells. Moreover, after binding to UACC-257 cells, rendomab-B4 is internalized and colocalizes with the endosomal protein EEA-1. Interestingly, rendomab-B4, despite its inability to compete with endothelin binding, is able to inhibit phospholipase C pathway and migration induced by endothelin. By contrast, rendomab-B4 fails to decrease ERK1/2 phosphorylation induced by endothelin, suggesting a biased effect on ETB. These particular properties make rendomab-B4 an interesting tool to analyze ETB-structure/function and a promising starting point for the development of new immunological tools in the field of melanoma therapeutics.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Antineoplásicos/farmacología , Antagonistas de los Receptores de la Endotelina B/farmacología , Melanoma , Receptor de Endotelina B/inmunología , Línea Celular Tumoral , Humanos
7.
Cell Signal ; 14(4): 341-9, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11858941

RESUMEN

We previously described that pervanadate, a potent tyrosine phosphatase inhibitor, induced contraction of rat myometrium via phospholipase (PL) C-gamma1 activation [Biol Reprod 54 (1996) 1383]. In this study, we found that pervanadate induced tyrosine phosphorylation of the platelet-derived growth factor (PDGF)-beta receptor, interaction of the phosphorylated PDGF receptor with the phosphorylated PLC-gamma1, production of inositol phosphates (InsPs), extracellular signal-regulated kinase (ERK) activation and DNA synthesis. All these responses were insensitive to PDGF receptor kinase inhibition or PDGF receptor down-regulation. We showed that Src family kinases were activated by pervanadate, and that InsPs production and phosphorylation of both PLC-gamma1 and the PDGF receptor were blocked by PP1, an Src inhibitor. In contrast, the stimulation of ERK by pervanadate was totally refractory to PP1. These results demonstrated that the activation of Src by pervanadate is involved in PLC-gamma1/InsPs signalling but does not play a major role in ERK activation.


Asunto(s)
Inhibidores Enzimáticos/farmacología , Miometrio/enzimología , Proteínas Tirosina Fosfatasas/antagonistas & inhibidores , Proteínas Proto-Oncogénicas pp60(c-src)/metabolismo , Vanadatos/farmacología , Animales , Células Cultivadas , ADN/biosíntesis , Femenino , Fosfatos de Inositol/biosíntesis , Isoenzimas/metabolismo , Cinética , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Miometrio/efectos de los fármacos , Miometrio/metabolismo , Fosfolipasa C gamma , Fosforilación , Fosfotirosina/metabolismo , Ratas , Ratas Wistar , Receptor beta de Factor de Crecimiento Derivado de Plaquetas/metabolismo , Transducción de Señal/efectos de los fármacos , Fosfolipasas de Tipo C/metabolismo
8.
Cell Signal ; 23(12): 1997-2004, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21803151

RESUMEN

Sphingosine 1-phosphate (S1P), a bioactive lipid generated by sphingosine kinases (SphK1/2), initiates different signalling pathways involved in physiological and pathological processes. We previously demonstrated that in rat myometrium at late (day 19) gestation, SphK1 increases the expression of COX2 via S1P generation and release. In rat uterine leiomyoma cells (ELT3), SphK1/S1P axis controls survival and proliferation. In the present study we demonstrate that PDBu activates SphK1 but not SphK2. SphK1 activation requires PKC and MAPK ERK1/2. S1P produced by PDBu is released in the medium. PDBu-induced S1P export is abolished by Ro-318220 and BIM (PKC inhibitors), by U0126 and PD98059 (MEK inhibitors), SKI-II (SphKI/2 inhibitor) and SphK1-siRNA, suggesting the involvement of PKC, ERK and SphK1 respectively. The release of S1P is insensitive to inhibitors of ATP Binding Cassette (ABC)A1 and ABCB1 transporters, but is abolished when ABCC1 transporters are inhibited by MK571 or down-regulated by ABCC1-siRNA. PDBu increases COX2 expression that is blocked by the inhibition of PKC, ERK1/2, SphK1, and when cells are treated with MK571 or transfected with ABCC1-siRNA. The induction of COX2 by the S1P release due to PDBu or by exogenous S1P involves S1P2 receptors coupled to Gi. In myometrium from rat at late gestation, the release of S1P is also strongly reduced when SphK and ABCC1 are inhibited. The data reveal that in rat leiomyoma cells and late pregnant rat myometrium, the release of S1P involves a similar signalling pathway and occurs through ABCC1.


Asunto(s)
Lisofosfolípidos/metabolismo , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Miometrio/metabolismo , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Esfingosina/análogos & derivados , Animales , Línea Celular Tumoral , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Pruebas de Enzimas , Femenino , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/metabolismo , Expresión Génica , Técnicas de Silenciamiento del Gen , Leiomioma , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/antagonistas & inhibidores , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/genética , Fosfotransferasas (Aceptor de Grupo Alcohol)/genética , Embarazo , Propionatos/farmacología , Proteína Quinasa C/metabolismo , Quinolinas/farmacología , Interferencia de ARN , Ratas , Ratas Wistar , Receptores de Lisoesfingolípidos/metabolismo , Esfingosina/metabolismo , Neoplasias Uterinas
9.
Int J Biochem Cell Biol ; 43(3): 299-302, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20974279

RESUMEN

Endothelin-1 (ET-1), a member of endothelin peptide family is released by many different tissues including uterine smooth muscle. ET-1 acts through ETA and ETB receptors and is implicated in a wide range of biological and pathological functions that explain the great attention of the pharmacological industry for ET-1 receptors as potential therapeutic targets in vascular pathologies and cancers. It is now well established that ET-1 is also able to regulate myometrial functions. In the present review, we focused on ET axis and related signaling pathways involved in the regulation of myometrial contraction, as well as cell proliferation and survival. Such ET-1-mediated cellular functions play a critical role in normal pregnancy, preterm birth and uterine leiomyoma.


Asunto(s)
Endotelina-1/metabolismo , Miometrio/metabolismo , Miometrio/patología , Secuencia de Aminoácidos , Enfermedad , Endotelina-1/química , Femenino , Humanos , Datos de Secuencia Molecular , Transducción de Señal , Contracción Uterina
10.
Am J Physiol Cell Physiol ; 292(1): C240-50, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16956968

RESUMEN

Sphingosine 1-phosphate (S1P), a bioactive sphingolipid involved in diverse biological processes, is generated by sphingosine kinase (SphK) and acts via intracellular and/or extracellular mechanisms. We used biochemical, pharmacological, and physiological approaches to investigate in rat myometrium the contractile effect of exogenous S1P and the possible contribution of SphK in endothelin-1 (ET-1)-mediated contraction. S1P stimulated uterine contractility (EC(50) = 1 microM and maximal response = 5 microM) by a pertussis toxin-insensitive and a phospholipse C (PLC)-independent pathway. Phosphorylated FTY720, which interacts with all S1P receptors, except S1P(2) receptors, failed to mimic S1P contractile response, indicating that the effects of S1P involved S1P(2) receptors that are expressed in myometrium. Contraction mediated by S1P and ET-1 required extracellular calcium and Rho kinase activation. Inhibition of SphK reduced ET-1-mediated contraction. ET-1, via ET(A) receptors coupled to pertussis toxin-insensitive G proteins, stimulated SphK1 activity and induced its translocation to the membranes. Myometrial contraction triggered by ET-1 is consecutive to the sequential activation of PLC, protein kinase C, SphK1 and Rho kinase. Prolonged exposure of the myometrium to S1P downregulated S1P(2) receptors and abolished the contraction induced by exogenous S1P. However, in these conditions, the tension triggered by ET-1 was not reduced, indicating that SphK activated by ET-1 contributed to its contractile effect via a S1P(2) receptor-independent process. Our findings demonstrated that exogenous S1P and SphK activity regulated myometrial contraction and may be of physiological relevance in the regulation of uterine motility during gestation and parturition.


Asunto(s)
Endotelina-1/farmacología , Lisofosfolípidos/farmacología , Miometrio , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Esfingosina/análogos & derivados , Contracción Uterina , Animales , Transporte Biológico/efectos de los fármacos , Calcio/fisiología , Citosol/metabolismo , Activación Enzimática , Líquido Extracelular/metabolismo , Femenino , Proteínas de Unión al GTP/efectos de los fármacos , Proteínas de Unión al GTP/metabolismo , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Miometrio/efectos de los fármacos , Miometrio/enzimología , Miometrio/fisiología , Toxina del Pertussis/farmacología , Proteína Quinasa C/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Ratas , Ratas Wistar , Receptores de Superficie Celular/metabolismo , Receptores de Superficie Celular/fisiología , Receptores de Lisoesfingolípidos/metabolismo , Esfingosina/farmacología , Fosfolipasas de Tipo C/metabolismo , Contracción Uterina/fisiología , Proteínas de Unión al GTP rho/metabolismo , Quinasas Asociadas a rho
11.
Biol Reprod ; 76(4): 681-91, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17202387

RESUMEN

Surfactant protein A (SFTPA1), a member of the collagenous lectin (collectin) family, was first described as a major constituent of lung surfactant, but has recently also been found in the female genital tract. Various microorganisms colonize this area and may cause intrauterine infection or trigger preterm labor. We found that SFTPA1 was not produced in the uterus. Instead, it was immunodetected transiently in rat myometrium at the end (Days 19 and 21) of gestation, but not postpartum, and in cultured myometrial cells. Fluorescence microscopy showed that Texas Red-labeled SFTPA1 bound to myometrial cells. This result was confirmed by biochemical approaches. [(125)I]-SFTPA1 bound to two myometrial cell proteins (55 and 210 kDa). This interaction was dependent on the integrity of the collagenlike domain of SFTPA1. SFTPA1 rapidly activated mitogen-activated protein kinase 1/3 (MAPK1/3) in myometrial cells. Bacterial lipopolysaccharide (LPS), an agent known to trigger uterine contractions and preterm birth, also activated MAPK1/3. The prolonged treatment of myometrial cells with LPS or SFTPA1 upregulated PTGS2 (COX2) protein levels. The addition of rough-type LPS to SFTPA1 blocked the interaction of SFTPA1 with its binding sites and the activation of MAPK1/3 and PTGS2 by SFTPA1. Our data provide the first demonstration of a direct effect of SFTPA1 on rat myometrial cells and inhibitory cross talk between SFTPA1 and LPS signals, providing new insight into the mechanisms of normal and preterm parturition.


Asunto(s)
Lipopolisacáridos/farmacología , Miometrio/efectos de los fármacos , Miometrio/metabolismo , Preñez , Proteína A Asociada a Surfactante Pulmonar/metabolismo , Animales , Sitios de Unión , Células Cultivadas , Ciclooxigenasa 2/metabolismo , Femenino , Edad Gestacional , Microscopía Fluorescente , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Embarazo , Unión Proteica , Proteína A Asociada a Surfactante Pulmonar/farmacología , Ratas , Ratas Wistar , Transducción de Señal/efectos de los fármacos
12.
Biol Reprod ; 72(1): 69-77, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15355882

RESUMEN

Endothelin (ET)-1 is a mitogenic factor in numerous cell types, including rat myometrial cells. In the present study, we investigated the potential role of ET-1 in the proliferation of tumoral uterine smooth muscle cells (ELT-3 cells). We found that ET-1 exerted a more potent mitogenic effect in ELT-3 cells than in normal myometrial cells, as indicated by the increase in [3H]thymidine incorporation, cell number, and bromodeoxyuridine incorporation. The ET-1 was more efficient than platelet-derived growth factor and epidermal growth factor to stimulate proliferation. The ET-1-mediated cell proliferation was inhibited in the presence of U0126, a specific inhibitor of (mitogen-activated protein kinase ERK kinase), indicating that extracellular signal-regulated kinase (ERK) activation is involved. Additionally, ET-1 induced the activation of phospholipase (PL) D, leading to the synthesis of phosphatidic acid (PA). The ET-1-induced activation of PLD was twofold higher in ELT-3 cells compared to that in normal cells. The two cell types expressed mRNA for PLD1a and PLD2, whereas PLD1b was expressed only in ELT-3 cells. The exposure of cells to butan-1-ol reduced ET-1-mediated production of PA by PLD and partially inhibited ERK activation and DNA synthesis. Addition of exogenous PLD or PA in the medium reproduced the effect of ET-1 on ERK activation and cell proliferation. Collectively, these data indicate that ET-1 is a potent mitogenic factor in ELT-3 cells via a signaling pathway involving a PLD-dependent activation of ERK. This highlights the potential role of ET-1 in the development of uterine leiomyoma, and it reinforces the role of PLD in tumor growth.


Asunto(s)
Endotelina-1/metabolismo , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Leiomioma/metabolismo , Fosfolipasa D/metabolismo , Neoplasias Uterinas/metabolismo , Animales , Butadienos/farmacología , Proliferación Celular , Endotelina-1/farmacología , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Quinasas MAP Reguladas por Señal Extracelular/antagonistas & inhibidores , Femenino , Leiomioma/patología , Masculino , Nitrilos/farmacología , Ácidos Fosfatidicos/metabolismo , Fosfolipasa D/efectos de los fármacos , Fosfolipasa D/genética , Proteína Quinasa C/efectos de los fármacos , Proteína Quinasa C/metabolismo , Ratas , Ratas Wistar , Transducción de Señal , Neoplasias Uterinas/patología
13.
Am J Physiol Cell Physiol ; 283(1): C251-60, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12055094

RESUMEN

In this study, we analyzed in rat myometrial cells the signaling pathways involved in the endothelin (ET)-1-induced extracellular signal-regulated kinase (ERK) activation required for the induction of DNA synthesis. We found that inhibition of protein kinase C (PKC) by Ro-31-8220 abolished ERK activation. Inhibition of phospholipase C (PLC) by U-73122 or of phosphoinositide (PI) 3-kinase by wortmannin partially reduced ERK activation. A similar partial inhibition was observed after treatment with pertussis toxin or PKC downregulation by phorbol ester treatment. The effect of wortmannin was additive with that produced by PKC downregulation but not with that due to pertussis toxin. These results suggest that both diacylglycerol-sensitive PKC, activated by PLC products, and diacylglycerol-insensitive PKC, possibly activated by a G(i)-PI 3-kinase-dependent process, are involved in ET-1-induced ERK activation. These two pathways were found to be activated mainly through the ET(A) receptor subtype. ET-1 and phorbol ester stimulated Src activity in a PKC-dependent manner, both responses being abolished in the presence of Ro-31-8220. Inhibition of Src kinases by PP1 abrogated phorbol ester- and ET-1-induced ERK activation. Finally, ET-1 activated Ras in a PP1- and Ro-31-8220-sensitive manner. Altogether, our results indicate that ET-1 induces ERK activation in rat myometrial cells through the sequential stimulation of PKC, Src, and Ras.


Asunto(s)
Endotelina-1/farmacología , Proteínas Quinasas Activadas por Mitógenos/fisiología , Proteína Quinasa C/metabolismo , Familia-src Quinasas/metabolismo , Animales , Células Cultivadas , Activación Enzimática/fisiología , Receptores ErbB/fisiología , Femenino , Proteínas de Unión al GTP/fisiología , Mitógenos/farmacología , Miometrio/citología , Miometrio/enzimología , Toxina del Pertussis , Fosfatidilinositol 3-Quinasas/fisiología , Ratas , Ratas Wistar , Receptores del Factor de Crecimiento Derivado de Plaquetas/fisiología , Transducción de Señal/efectos de los fármacos , Activación Transcripcional/fisiología , Fosfolipasas de Tipo C/metabolismo , Factores de Virulencia de Bordetella/farmacología , Proteínas ras/fisiología
14.
Am J Physiol Cell Physiol ; 286(4): C798-806, 2004 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-14644778

RESUMEN

Endothelin-1 (ET-1), platelet-derived growth factor (PDGF), and epidermal growth factor (EGF) stimulated thymidine incorporation with different efficiency (PDGF >> EGF = ET-1) in rat myometrial cells. They also stimulated ERK activation, which culminated at 5 min and then declined to reach a plateau (at 45 min: EGF > 90%, PDGF = 50%, and ET-1 < 10% of maximum). Inhibition and downregulation of PKC demonstrated that ERK activation at 5 min involved PKC delta and -zeta for ET-1 and PKC alpha plus another PKC isoform for PDGF. By contrast, the EGF response did not involve PKC. Stimulation of Ras was more important with EGF than with PDGF, with ET-1 being the weakest activator. The simultaneous incubation of the cells with EGF and ET-1 potentiated the ERK activation at 5 min and mimicked the plateau phase obtained with PDGF. Under these conditions thymidine incorporation was comparable to that induced by PDGF. Taken together, our results indicated that the kinetic profile of ERK activation and its impact on cell proliferation can be modulated by the differential involvement of PKC isoforms and the amplitude of Ras activation.


Asunto(s)
Endotelina-1/farmacología , Factor de Crecimiento Epidérmico/farmacología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Miometrio/enzimología , Factor de Crecimiento Derivado de Plaquetas/farmacología , Proteína Quinasa C/metabolismo , Animales , Células Cultivadas , Sinergismo Farmacológico , Femenino , Mitógenos/farmacología , Músculo Liso/citología , Músculo Liso/efectos de los fármacos , Músculo Liso/enzimología , Miometrio/citología , Miometrio/efectos de los fármacos , Proteína Quinasa C-alfa , Proteína Quinasa C-delta , Proteína Quinasa C-epsilon , Ratas , Ratas Wistar , Receptor de Endotelina A/metabolismo , Fosfolipasas de Tipo C/metabolismo , Proteínas ras/metabolismo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda